publication date: Dec. 14, 2018
To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
Around March, my friend Howard Ozer told me he was heading out on a safari. He did these things often, adding to his collection of trophies.
Breast cancer research is big business. And the incentives in that business are designed to benefit industry, doctors and institutions, leaving patients behind. In 2018 alone, about $1 billion federal dollars were invested in institutions around the country to fund research.
- Anil Rustgi named cancer center director at Columbia, New York-Presbyterian
- Jasmin Tiro to focus on assessing, meeting cancer needs in Dallas/Fort Worth area
- Leigh Boehmer named medical director of education at the ACCC
- Pentecost Foundation gifts $3 million to Moffitt
- Kadcyla cut risk of disease recurrence vs. Herceptin in HER2-positive early breast cancer with residual disease after neoadjuvant treatment
- BYL719 + fulvestrant improved PFS in PIK3CA mutated HR+/HER2- advanced breast cancer
- Data show efficacy, tolerability of Kisqali combination in HR+/HER2- advanced breast cancer with visceral disease
- Insight Genetics launches test for triple negative breast cancer
- Biotheranostics presents data on the Breast Cancer Index
- First-line immunotherapy combination fails to improve OS in lung cancer
- Amifostine delays onset of acute esophagitis for small cell lung cancer patients
- European Commission adopted positive opinion of rucaparib in platinum-based chemotherapy
- FDA grants orphan drug designation to Merck’s M7824 in biliary tract cancer
